Lowenstein conducted critical expedited intellectual property diligence in support of a $350 million carve-out acquisition by Phibro Animal Health Corp. of Zoetis’ global medicated feed additives business, which includes 37 product lines sold in over 80 countries covered by more than 553 trademarks. The deal is expected to be finalized in the second half of 2024.
This product portfolio generated approximately $400 million in revenue in 2023. The sale would allow Parsippany-headquartered Zoetis to focus its investments on other solutions, such as vaccine, biologic and genetic programs. More than 300 Zoetis MFA colleagues are expected to transition to Phibro to support this business.
Lowenstein will commence coordinating with foreign agents to maintain trademarks coming due for renewal or proof of use, working closely with the Phibro team to renew the correct group of marks, and then coordinating with Zoetis to handle these actions quickly before closing. After closing, we will assume full responsibility for integration and ongoing management of all aspects of this large portfolio of trusted animal health medicated feed additive brands.
Vanessa A. Ignacio, partner and Chair of Lowenstein’s Trademarks, Copyrights, Trade Secrets & Advertising practice, leads the Lowenstein’s Phibro trademark legal team, which also includes Matthew P. Hintz and Jenna-Marie Tracy.
